Insider Selling: TransMedics Group (NASDAQ:TMDX) CFO Sells $52,170.00 in Stock

TransMedics Group, Inc. (NASDAQ:TMDX) CFO Gerardo Hernandez sold 375 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $139.12, for a total value of $52,170.00. Following the completion of the sale, the chief financial officer owned 14,689 shares in the company, valued at $2,043,533.68. The trade was a 2.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Gerardo Hernandez also recently made the following trade(s):

• On Wednesday, March 4th, Gerardo Hernandez sold 7,236 shares of TransMedics Group stock. The stock was sold at an average price of $147.21, for a total transaction of $1,065,211.56.
• On Thursday, December 4th, Gerardo Hernandez sold 920 shares of TransMedics Group stock. The stock was sold at an average price of $139.62, for a total transaction of $128,450.40.

TransMedics Group Stock Down 7.3%

Shares of NASDAQ TMDX opened at $129.80 on Friday. The company’s 50 day moving average price is $135.35 and its 200-day moving average price is $126.90. The company has a debt-to-equity ratio of 1.06, a quick ratio of 6.59 and a current ratio of 7.14. TransMedics Group, Inc. has a 52-week low of $62.23 and a 52-week high of $156.00. The company has a market capitalization of $4.45 billion, a P/E ratio of 26.49 and a beta of 1.98.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. Morgan Stanley boosted their target price on shares of TransMedics Group from $123.00 to $135.00 and gave the company an “equal weight” rating in a report on Tuesday, December 2nd. JPMorgan Chase & Co. increased their price target on TransMedics Group from $114.00 to $149.00 and gave the stock a “neutral” rating in a report on Wednesday, February 25th. Piper Sandler lifted their price objective on TransMedics Group from $140.00 to $160.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. Oppenheimer boosted their price objective on TransMedics Group from $150.00 to $175.00 and gave the company an “outperform” rating in a research note on Wednesday, February 25th. Finally, Needham & Company LLC upped their target price on TransMedics Group from $166.00 to $174.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. Six research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $150.67.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of TMDX. Intech Investment Management LLC raised its holdings in shares of TransMedics Group by 28.9% in the 2nd quarter. Intech Investment Management LLC now owns 34,389 shares of the company’s stock worth $4,608,000 after acquiring an additional 7,713 shares during the last quarter. Nordea Investment Management AB acquired a new position in TransMedics Group during the 3rd quarter valued at about $4,070,000. Peregrine Capital Management LLC boosted its stake in TransMedics Group by 16.5% during the 3rd quarter. Peregrine Capital Management LLC now owns 68,406 shares of the company’s stock valued at $7,675,000 after purchasing an additional 9,676 shares during the last quarter. Intrust Bank NA bought a new stake in TransMedics Group during the 2nd quarter worth approximately $747,000. Finally, Lisanti Capital Growth LLC increased its holdings in TransMedics Group by 62.0% during the 3rd quarter. Lisanti Capital Growth LLC now owns 56,901 shares of the company’s stock worth $6,384,000 after purchasing an additional 21,771 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.